Literature DB >> 7593810

Effective treatment with alpha 1-protease inhibitor of chronic cutaneous vasculitis associated with alpha 1-antitrypsin deficiency.

S K Dowd1, G C Rodgers, J P Callen.   

Abstract

The primary serum proteinase inhibitor is alpha 1-antitrypsin, and deficiency of this enzyme has been associated with a variety of systemic and cutaneous disorders. We report cutaneous vasculitis in a 49-year-old man with alpha 1-antitrypsin deficiency. His condition persisted despite treatment with colchicine, prednisone, and antibiotics but has been controlled by the administration of alpha 1-protease inhibitor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7593810     DOI: 10.1016/0190-9622(95)90436-0

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  4 in total

1.  Rare case of eosinophilic granulomatosis with polyangiitis in two patients with α-1-antitrypsin deficiency (PiSZ).

Authors:  Jordan Maureen Moxey; Emma Victoria Low; Alice Margaret Turner
Journal:  BMJ Case Rep       Date:  2016-04-26

Review 2.  Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema.

Authors:  Ignacio Blanco; Beatriz Lara; Frederick de Serres
Journal:  Orphanet J Rare Dis       Date:  2011-04-12       Impact factor: 4.123

3.  The design of a new truncated and engineered alpha1-antitrypsin based on theoretical studies: an antiprotease therapeutics for pulmonary diseases.

Authors:  Nazanin Pirooznia; Sadegh Hasannia; Seyed Shahriar Arab; Abbas Sahebghadam Lotfi; Mostafa Ghanei; Abbas Shali
Journal:  Theor Biol Med Model       Date:  2013-05-24       Impact factor: 2.432

Review 4.  The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals.

Authors:  Danielle M Dunlea; Laura T Fee; Thomas McEnery; Noel G McElvaney; Emer P Reeves
Journal:  J Inflamm Res       Date:  2018-03-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.